Biological & Clinical Efficacy of Subcutaneous Recombina

Project: Research project

Description

Biological & Clinical Efficacy of Subcutaneous Recombinant Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy
StatusFinished
Effective start/end date11/11/0211/30/09

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

CD4 Lymphocyte Count
Interleukin-2
HIV
Therapeutics